Metadata
- Name
- COVID-19 Specific T Cell Derived Exosomes (CSTC-Exo)
- Repository
- ClinicalTrials.gov
- Identifier
- clinicaltrials:NCT04389385
- Description
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has caused mass
mortality in the last 3 months that necessitates urgent development of new therapeutical
agents. So far there is no effective anti-viral drug to reduce viral load that has critical
importance to prevent progress into severe viral pneumonia and systemic hyper inflammation
state. This project is to offer a biologic agent based on T cell derived exosomes. This is a
novel approach using our proprietary protocols for drug development. This clinical trial is
to test the safety and efficacy of this new agent following targeted delivery by metered dose
inhaler. The project have received proper approvals from the Turkish Ministry of Health and
Erciyes University, Kayseri Turkey. Turk-Patent Application Number: PCT/TR2020/050302 - Data or Study Types
- clinical trial
- Keywords
- Exosome, Virus specific T cell, COVID-19, Pnemonia, Cell therapy, Corona virus
- Source Organization
- Unknown
- Access Conditions
- available
- Year
- 2020
- Access Hyperlink
- https://clinicaltrials.gov/ct2/show/NCT04389385
Distributions
- Encoding Format: HTML ; URL: https://clinicaltrials.gov/ct2/show/results/NCT04389385